Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Karthik Sabapathy

Pain Medicine Southlake, TX Doctor of Osteopathy

NPI 1124482740 CMS profile 5702913

1110 E State Highway 114 Ste 100, Ste 150, Southlake, TX 76092

Open in the dashboard

General payments

$18,182

289 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Karthik Sabapathy of Southlake, TX is reported in the CMS Open Payments database as having received $18,182 across 289 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $777 41
2024 General $3,015 63
2023 General $5,856 83
2022 General $5,053 61
2021 General $2,192 26
2020 General $557 7
2019 General $732 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karthik Sabapathy
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Karthik Sabapathy were reported at $777. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Karthik Sabapathy Pain Medicine median Middle half National median
2019 $732 $506 $144–$1,566 $163
2020 $557 $315 $96–$934 $114
2021 $2,192 $452 $134–$1,237 $132
2022 $5,053 $475 $124–$1,407 $149
2023 $5,856 $480 $136–$1,384 $160
2024 $3,015 $521 $164–$1,511 $164
2025 $777 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $8,586 170 payments
  2. MML US, Inc. $2,982 22 payments
  3. Boston Scientific Corporation $1,422 23 payments
  4. Relievant Medsystems, Inc. $1,102 10 payments
  5. Nevro Corp. $1,094 16 payments
  6. SI-BONE, Inc. $1,060 10 payments
  7. Curonix LLC $628 8 payments
  8. Abbott Laboratories $175 1 payment
  9. SPR Therapeutics, Inc $164 2 payments
  10. Medtronic USA, Inc. $155 2 payments
  11. Other $815 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,537 248 payments
  2. Travel and Lodging $7,633 40 payments
  3. Education $13 1 payment
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $4,002 113 payments
  2. ReActiv8 $2,982 22 payments
  3. VANTA ADAPTIVESTIM $2,044 10 payments
  4. INTELLIS $1,748 20 payments
  5. Intracept Pain $1,102 10 payments
  6. Intracept Pain $1,102 10 payments
  7. Intracept Pain $1,102 10 payments
  8. Intracept Pain $1,102 10 payments
  9. IFUSE IMPLANT SYSTEM $955 7 payments
  10. Senza Spinal Cord Stimulation System $696 6 payments
  11. Other $4,383 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,715

Median for Pain Management: 951

Drug cost

$27,155

Median for Pain Management: $26,034

Branded share of claims

35.7%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 334 $6,501
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 48 $4,024
Pregabalin Generic 131 $2,815
Gabapentin Generic 258 $2,358
Fentanyl Generic 13 $2,175
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 81 $1,954
Duloxetine Hcl Generic 139 $1,426
Acetaminophen-Codeine Acetaminophen With Codeine Brand 114 $1,333
Tramadol Hcl Generic 151 $1,121
Celecoxib Generic 47 $595

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$108,631

Of which drugs: $5,227

Medicare patients

218

Average age 74

Services billed

2,072

138 women, 80 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 42%
Diabetes 33%
Ischemic heart disease 32%
Chronic kidney disease 28%
COPD 20%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 37 236 $175

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

289 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record